The head of BioNTech, the German company that developed the first Covid-19 vaccine, said a new formula is likely to be needed by mid-2022 to protect against future mutations of the virus.
The head of BioNTech, the German company that developed the first Covid-19 vaccine, said a new formula is likely to be needed by mid-2022 to protect against future mutations of the virus.
Ugur Sahin, co-founder and chief executive officer of BioNtech, told the Financial Times that while current variants of Covid-19, such as the contagious delta strain, were not different enough to undermine current vaccinations, new strains will emerge that can evade booster shots and the body’s immune defenses.
“This year [a different vaccine] is completely unneeded, but by mid-next year, it could be a different situation,” he said. “This is a continuous evolution, and that evolution has just started.”
BioNTech partnered with U.S. pharmaceuticals giant Pfizer to develop its Covid-19 vaccine. Last month, the companies submitted initial data to U.S. regulators about the use of the vaccine in children aged 5 to 11, one step closer to bringing shots to school-age kids.
In July Fin24 reported that Pfizer and BioNTech agreed to partner with SA’s Biovac Institute to make their Covid-19 vaccine at a facility in Cape Town and deliver more than 100 million doses annually to African nations.
We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can
trust. For only R75 per month, you have access to
a world of in-depth analyses, investigative journalism,
top opinions and a range of features. Journalism
strengthens democracy. Invest in the future today.
English
Arabic
Bulgarian
Chinese (Simplified)
Dutch
French
German
Italian
Portuguese
Russian
Spanish
Discussion about this post